Markus Zettl | Director Immuno, Oncology
Pieris Pharmaceuticals

Markus Zettl, Director Immuno, Oncology, Pieris Pharmaceuticals

Before joining Pieris Pharmaceuticals as Director Immuno-Oncology overseeing pre-clinical development of Pieris´s innovative pipeline projects, Dr. Zettl was Project Leader at Boehringer-Ingelheim from 2011, leading antibody programs in the field of Immuno-Oncology from early preclinical into clinical phases.
During his PhD and postdoctoral studies, he worked in a variety of areas of cancer biology at the EMBL in Heidelberg Germany and at the MRC-LMB in Cambridge UK. Research topics covered molecular mechanisms of how oncolytic viruses exploit the host cytoskeleton and the impact of metallo-protease (TACE) activation on cytokine and growth factor signalling with implications for cancer and inflammatory disorders.  Dr. Zettl authored numerous high impact publications and patents in the field of Immuno-Oncology. 

Appearances:



Festival of Biologics Day 1 @ 15:20

Enhancing Efficacy and Safety of 4-1BB Agonism with PRS-343, a Tumor-Targeted Bispecific

  • PRS-343 is the first bispecific to enter the clinic which is engineered to specifically activate 4- 1BB in the tumor microenvironment
  • PRS-343 demonstrated durable anti-tumor activity in heavily pre-treated patient populationacross multiple tumor types, including those usually not responsive to immune therapy; novel and non-redundant MoA among HER2- targeting therapies and checkpoint inhibition
last published: 17/Sep/21 16:05 GMT
last published: 17/Sep/21 16:05 GMT
last published: 17/Sep/21 16:05 GMT
last published: 17/Sep/21 16:05 GMT

back to speakers